225 related articles for article (PubMed ID: 19080745)
1. Insights into the biology of primary central nervous system lymphoma.
Mrugala MM; Rubenstein JL; Ponzoni M; Batchelor TT
Curr Oncol Rep; 2009 Jan; 11(1):73-80. PubMed ID: 19080745
[TBL] [Abstract][Full Text] [Related]
2. Advances in Pathobiology of Primary Central Nervous System Lymphoma.
Yang XL; Liu YB
Chin Med J (Engl); 2017 Aug; 130(16):1973-1979. PubMed ID: 28776551
[TBL] [Abstract][Full Text] [Related]
3. Primary central nervous system lymphoma: clinicopathological and genomic insights for therapeutic development.
Tateishi K; Miyake Y; Nakamura T; Yamamoto T
Brain Tumor Pathol; 2021 Jul; 38(3):173-182. PubMed ID: 34255226
[TBL] [Abstract][Full Text] [Related]
4. Promoter methylation attenuates SHP1 expression and function in patients with primary central nervous system lymphoma.
Liu J; Wang Y; Sun X; Ji N; Sun S; Wang Y; Liu F; Cui Q; Wang C; Liu Y
Oncol Rep; 2017 Feb; 37(2):887-894. PubMed ID: 27959415
[TBL] [Abstract][Full Text] [Related]
5. Histopathology, pathogenesis and molecular genetics in primary central nervous system lymphomas.
Nakamura M; Shimada K; Ishida E; Konishi N
Histol Histopathol; 2004 Jan; 19(1):211-9. PubMed ID: 14702189
[TBL] [Abstract][Full Text] [Related]
6. Angiogenesis in primary central nervous system lymphoma (PCNSL).
Takeuchi H; Matsuda K; Kitai R; Sato K; Kubota T
J Neurooncol; 2007 Sep; 84(2):141-5. PubMed ID: 17406788
[TBL] [Abstract][Full Text] [Related]
7. Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas.
D'Haene N; Catteau X; Maris C; Martin B; Salmon I; Decaestecker C
Br J Haematol; 2008 Feb; 140(4):402-10. PubMed ID: 18081894
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry for c-myc and bcl-2 overexpression improves risk stratification in primary central nervous system lymphoma.
Hatzl S; Posch F; Deutsch A; Beham-Schmid C; Stöger H; Greinix H; Pichler M; Neumeister P; Prochazka KT
Hematol Oncol; 2020 Aug; 38(3):277-283. PubMed ID: 32101329
[TBL] [Abstract][Full Text] [Related]
9. Targeting the tumor microenvironment in primary central nervous system lymphoma: Implications for prognosis.
Shi H; Sun X; Wu Y; Cui Q; Sun S; Ji N; Liu Y
J Clin Neurosci; 2024 Jun; 124():36-46. PubMed ID: 38642434
[TBL] [Abstract][Full Text] [Related]
10. Expression of immunoglobulin transcription factors in primary intraocular lymphoma and primary central nervous system lymphoma.
Coupland SE; Loddenkemper C; Smith JR; Braziel RM; Charlotte F; Anagnostopoulos I; Stein H
Invest Ophthalmol Vis Sci; 2005 Nov; 46(11):3957-64. PubMed ID: 16249468
[TBL] [Abstract][Full Text] [Related]
11. A clinicopathological study of primary central nervous system lymphomas & their association with Epstein-Barr virus.
Sharma MC; Gupta RK; Kaushal S; Suri V; Sarkar C; Singh M; Kale SS; Sahoo RK; Kumar L; Raina V
Indian J Med Res; 2016 May; 143(5):605-15. PubMed ID: 27488004
[TBL] [Abstract][Full Text] [Related]
12. Expression of survivin, platelet-derived growth factor A (PDGF-A) and PDGF receptor alpha in primary central nervous system lymphoma.
Karabatsou K; Pal P; Dodd S; Mat A; Haylock B; Aguirreburualde M; Moxam N; Pinson-Ellis W; Broome J; Rainov NG
J Neurooncol; 2006 Sep; 79(2):171-9. PubMed ID: 16850112
[TBL] [Abstract][Full Text] [Related]
13. Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.
Braggio E; Van Wier S; Ojha J; McPhail E; Asmann YW; Egan J; da Silva JA; Schiff D; Lopes MB; Decker PA; Valdez R; Tibes R; Eckloff B; Witzig TE; Stewart AK; Fonseca R; O'Neill BP
Clin Cancer Res; 2015 Sep; 21(17):3986-94. PubMed ID: 25991819
[TBL] [Abstract][Full Text] [Related]
14. Primary central nervous system lymphoma: a study of clinicopathological features and trend in western India.
Pasricha S; Gupta A; Gawande J; Trivedi P; Patel D
Indian J Cancer; 2011; 48(2):199-203. PubMed ID: 21768666
[TBL] [Abstract][Full Text] [Related]
15. Emerging insights into origin and pathobiology of primary central nervous system lymphoma.
You H; Wei L; Kaminska B
Cancer Lett; 2021 Jul; 509():121-129. PubMed ID: 33766752
[TBL] [Abstract][Full Text] [Related]
16. Frequent Gene Mutations and Their Possible Roles in the Pathogenesis, Treatment and Prognosis of Primary Central Nervous System Lymphoma.
Jin Q; Jiang H; Han Y; Li C; Zhang L; Zhang Y; Chai Y; Zeng P; Yue L; Wu C
World Neurosurg; 2023 Feb; 170():99-106. PubMed ID: 36396049
[TBL] [Abstract][Full Text] [Related]
17. Advances and challenges in the treatment of primary central nervous system lymphoma.
Yang H; Xun Y; Yang A; Liu F; You H
J Cell Physiol; 2020 Dec; 235(12):9143-9165. PubMed ID: 32420657
[TBL] [Abstract][Full Text] [Related]
18. Prognostic markers for immunodeficiency-associated primary central nervous system lymphoma.
Kaulen LD; Galluzzo D; Hui P; Barbiero F; Karschnia P; Huttner A; Fulbright R; Baehring JM
J Neurooncol; 2019 Aug; 144(1):107-115. PubMed ID: 31190317
[TBL] [Abstract][Full Text] [Related]
19. Novel agents for primary central nervous system lymphoma: evidence and perspectives.
Illerhaus G; Schorb E; Kasenda B
Blood; 2018 Aug; 132(7):681-688. PubMed ID: 29986908
[TBL] [Abstract][Full Text] [Related]
20. Treatment of primary central nervous system lymphoma.
Ekenel M; DeAngelis LM
Curr Neurol Neurosci Rep; 2007 May; 7(3):191-9. PubMed ID: 17488584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
